# OnCo record nadofaragene-firadenovec (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nadofaragene-firadenovec/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nadofaragene-firadenovec" ;
  schema:name "Nadofaragene firadenovec"@en ;
  schema:description "Nadofaragene firadenovec is the first gene therapy for bladder cancer: a virus that makes bladder cells produce interferon for weeks, given once every three months."@en ;
  schema:url <https://onco.cc/drugs/nadofaragene-firadenovec/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nadofaragene_firadenovec> ;
  owl:sameAs <http://www.wikidata.org/entity/Q115779373> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Nadofaragene%20firadenovec> ;
  onco:status "approved" ;
  onco:modality "Non-replicating adenoviral gene therapy (intravesical)" ;
  schema:alternateName "Adstiladrin" ;
  onco:approval "US 2022: BCG-unresponsive high-risk NMIBC with CIS ± papillary tumours", "EU 2026: BCG-unresponsive NMIBC with CIS; 28 May 2026 (conditional)" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/bcg-and-intravesical-therapy/> ;
  onco:companies <https://onco.cc/companies/ferring/> ;
  onco:terms <https://onco.cc/terms/bcg-unresponsive/> ;
  onco:trials <https://onco.cc/trials/nct06510374/>, <https://onco.cc/trials/nct06545955/> .